Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

First Posted Date
2003-12-11
Last Posted Date
2023-06-05
Lead Sponsor
University of California, San Diego
Target Recruit Count
5
Registration Number
NCT00074269
Locations
🇺🇸

Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

First Posted Date
2003-11-25
Last Posted Date
2009-02-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
207
Registration Number
NCT00002989
Locations
🇮🇹

Ospedale San Eugenio, Rome, Italy

🇧🇪

Institut Jules Bordet, Brussels (Bruxelles), Belgium

🇩🇪

Eberhard Karls Universitaet, Tuebingen, Germany

and more 6 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

First Posted Date
2003-10-09
Last Posted Date
2014-02-13
Lead Sponsor
Children's Oncology Group
Target Recruit Count
42
Registration Number
NCT00017368
Locations
🇺🇸

CCOP - Columbia River Oncology Program, Portland, Oregon, United States

🇺🇸

Floating Hospital for Children, Boston, Massachusetts, United States

🇺🇸

CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

and more 6 locations

Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma

First Posted Date
2003-10-07
Last Posted Date
2014-02-13
Lead Sponsor
Children's Oncology Group
Target Recruit Count
31
Registration Number
NCT00070200
Locations
🇺🇸

Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States

🇺🇸

Children's Memorial Hospital - Chicago, Chicago, Illinois, United States

🇦🇺

Westmead Hospital, Westmead, New South Wales, Australia

and more 3 locations

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

First Posted Date
2003-10-07
Last Posted Date
2013-10-17
Lead Sponsor
Children's Oncology Group
Target Recruit Count
24
Registration Number
NCT00070187
Locations
🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 60 locations

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

First Posted Date
2003-08-11
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
899
Registration Number
NCT00002548
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

New England Medical Center Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 31 locations

Randomized Double Cord Blood Transplant Study

First Posted Date
2003-08-11
Last Posted Date
2019-05-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
110
Registration Number
NCT00067002
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

First Posted Date
2003-07-09
Last Posted Date
2018-08-09
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
104
Registration Number
NCT00064337
Locations
🇺🇸

Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States

🇺🇸

Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States

🇺🇸

St. Peter's Hospital, Helena, Montana, United States

and more 31 locations

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

First Posted Date
2003-05-07
Last Posted Date
2013-05-09
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
451
Registration Number
NCT00060255
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

First Posted Date
2003-05-02
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
13
Registration Number
NCT00003926
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy